Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Dividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ani Pharmaceuticals (ANIP) Change in Account Payables (2016 - 2025)

Historic Change in Account Payables for Ani Pharmaceuticals (ANIP) over the last 14 years, with Q3 2025 value amounting to $13.8 million.

  • Ani Pharmaceuticals' Change in Account Payables rose 54709.32% to $13.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $15.6 million, marking a year-over-year increase of 5446.43%. This contributed to the annual value of $479000.0 for FY2024, which is 9365.73% down from last year.
  • Per Ani Pharmaceuticals' latest filing, its Change in Account Payables stood at $13.8 million for Q3 2025, which was up 54709.32% from $3.1 million recorded in Q2 2025.
  • Ani Pharmaceuticals' 5-year Change in Account Payables high stood at $13.8 million for Q3 2025, and its period low was -$9.1 million during Q3 2022.
  • Its 5-year average for Change in Account Payables is $2.4 million, with a median of $2.8 million in 2023.
  • Examining YoY changes over the last 5 years, Ani Pharmaceuticals' Change in Account Payables showed a top increase of 75323.0% in 2022 and a maximum decrease of 60232.2% in 2022.
  • Over the past 5 years, Ani Pharmaceuticals' Change in Account Payables (Quarter) stood at $9.8 million in 2021, then grew by 3.02% to $10.1 million in 2022, then tumbled by 72.38% to $2.8 million in 2023, then crashed by 345.36% to -$6.8 million in 2024, then soared by 301.82% to $13.8 million in 2025.
  • Its Change in Account Payables was $13.8 million in Q3 2025, compared to $3.1 million in Q2 2025 and $5.5 million in Q1 2025.